Literature DB >> 24497538

Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism.

Clive Kearon1, Elie A Akl.   

Abstract

It takes about 3 months to complete "active treatment" of venous thromboembolism (VTE), with further treatment serving to prevent new episodes of thrombosis ("pure secondary prevention"). Consequently, VTE should generally be treated for either 3 months or indefinitely (exceptions will be described in the text). The decision to stop anticoagulants at 3 months or to treat indefinitely is dominated by the long-term risk of recurrence, and secondarily influenced by the risk of bleeding and by patient preference. VTE provoked by a reversible risk factor, or a first unprovoked isolated distal (calf) deep vein thrombosis (DVT), has a low risk of recurrence and is usually treated for 3 months. VTE associated with active cancer, or a second unprovoked VTE, has a high risk of recurrence and is usually treated indefinitely. The decision to stop anticoagulants at 3 months or to treat indefinitely is more finely balanced after a first unprovoked proximal DVT or pulmonary embolism (PE). Indefinite anticoagulation is often chosen if there is a low risk of bleeding, whereas anticoagulation is usually stopped at 3 months if there is a high risk of bleeding. The decision to continue anticoagulation indefinitely after a first unprovoked proximal DVT or PE is strengthened if the patient is male, the index event was PE rather than DVT, and/or d-dimer testing is positive 1 month after stopping anticoagulant therapy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24497538     DOI: 10.1182/blood-2013-12-512681

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  50 in total

1.  Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 2: treatment.

Authors:  J C Easaw; M A Shea-Budgell; C M J Wu; P M Czaykowski; J Kassis; B Kuehl; H J Lim; M MacNeil; D Martinusen; P A McFarlane; E Meek; O Moodley; S Shivakumar; V Tagalakis; S Welch; P Kavan
Journal:  Curr Oncol       Date:  2015-04       Impact factor: 3.677

Review 2.  The Intrinsic Pathway of Coagulation as a Target for Antithrombotic Therapy.

Authors:  Allison P Wheeler; David Gailani
Journal:  Hematol Oncol Clin North Am       Date:  2016-10       Impact factor: 3.722

3.  The cost-effectiveness and cost-utility analysis of the use of enoxaparin compared with heparin for venous thromboembolism prophylaxis in medical inpatients in Iran.

Authors:  Mohammadreza Amirsadri; Sarah Mousavi; Ali Karimipour
Journal:  Daru       Date:  2019-07-31       Impact factor: 3.117

Review 4.  The economic burden of incident venous thromboembolism in the United States: A review of estimated attributable healthcare costs.

Authors:  Scott D Grosse; Richard E Nelson; Kwame A Nyarko; Lisa C Richardson; Gary E Raskob
Journal:  Thromb Res       Date:  2015-11-24       Impact factor: 3.944

5.  Evaluation of meteorological and epidemiological characteristics of fatal pulmonary embolism.

Authors:  Klára Törő; Rita Pongrácz; Judit Bartholy; Aletta Váradi-T; Boglárka Marcsa; Brigitta Szilágyi; Attila Lovas; György Dunay; Péter Sótonyi
Journal:  Int J Biometeorol       Date:  2015-07-17       Impact factor: 3.787

Review 6.  Medical management of tumor lysis syndrome, postprocedural pain, and venous thromboembolism following interventional radiology procedures.

Authors:  Ali Faramarzalian; Keith B Armitage; Baljendra Kapoor; Sanjeeva P Kalva
Journal:  Semin Intervent Radiol       Date:  2015-06       Impact factor: 1.513

Review 7.  Role of thrombophilia testing: con.

Authors:  Scott M Stevens
Journal:  J Thromb Thrombolysis       Date:  2015-04       Impact factor: 2.300

Review 8.  Elite athletes and anticoagulant therapy: an intermittent dosing strategy.

Authors:  Stephan Moll; Joshua N Berkowitz; Christopher W Miars
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 9.  [Anticoagulation in patients with chronic kidney disease : Recommendations from the working group "Heart-Kidney" of the German Cardiac Society and the German Society of Nephrology].

Authors:  G Schlieper; V Schwenger; A Remppis; T Keller; R Dechend; S Massberg; S Baldus; T Weinreich; G Hetzel; J Floege; F Mahfoud; D Fliser
Journal:  Internist (Berl)       Date:  2017-05       Impact factor: 0.743

Review 10.  Plasma contact factors as therapeutic targets.

Authors:  Benjamin F Tillman; Andras Gruber; Owen J T McCarty; David Gailani
Journal:  Blood Rev       Date:  2018-04-12       Impact factor: 8.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.